Copyright
©The Author(s) 2025.
World J Clin Oncol. Jul 24, 2025; 16(7): 107109
Published online Jul 24, 2025. doi: 10.5306/wjco.v16.i7.107109
Published online Jul 24, 2025. doi: 10.5306/wjco.v16.i7.107109
Figure 3 Thymopoietin mRNA exhibits higher expression in papillary thyroid carcinoma.
A: Comparison with normal tissues shows higher thymopoietin (TMPO) mRNA expression in papillary thyroid carcinoma (PTC); B and C: Bias tests reveal no significant publication bias; D: Summary receiver operating characteristic indicates TMPO has discriminative capability in PTC. SMD: Standardized mean difference; SROC: Summary receiver operating characteristic.
- Citation: Song C, Pang YY, Lu SY, Li B, Li DM, He RQ, Qin DY, Li SD, Qv N, Chen YM, Chen G, He J, Jiang XB. Molecular mechanisms of thymopoietin in papillary thyroid cancer: Multiplatform gene expression data, gene knockout screening, and in-house immunohistochemistry. World J Clin Oncol 2025; 16(7): 107109
- URL: https://www.wjgnet.com/2218-4333/full/v16/i7/107109.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i7.107109